The Training of Resident Surgeons in Single-Port Thoracoscopic Surgery Wound Position Selection

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Taiwan University Hospital

About this trial

the metaverse system applied to the training of wound location selection for singleport thoracoscopic surgery. The experimental design is two groups of 40 computer tomography located superficially less than 2 cm lung nodule patients, one group uses the metaverse system to let resident physicians simulate the wound position on the digital twin organs of each patient, and the other group does not use it. The investigators will evaluate the surgeon's satisfaction with the surgical wound position and urgicalrelated results (such as surgery time, blood loss, etc.). The investigators expect that the system will help improve the appropriateness of resident physicians' choice of wound location for high-difficulty single-port thoracoscopic surgery, help them cross the first threshold necessary to familiarize themselves with the surgery faster, and accelerate learning.

Eligibility criteria

Qualifiers

Aged 18 years or older.

Diagnosed with a lung nodule no larger than 2cm in diameter. The lesion depth must be located within the outer third of the lung.

Scheduled to undergo computer tomography-guided single-port thoracoscopic wedge resection at National Taiwan University Hospital (NTUH) or National Taiwan Cancer Center (NTUCC).

Participants who have provided written informed consent for their imaging data to be used by the team to create digital twin models.

Disqualifiers

Patients with lesions larger than 2 cm.

Patients not planned for single-port thoracoscopic wedge resection with computed tomography localization.

Patients who have not provided written consent.

Members of vulnerable populations.

Trial design

Treatments tested in this trial

  • Metaverse system (Patients)
  • Metaverse system (Resident Physician)

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

This trial has no locations